Reducing Treatment Burden of Pegloticase for Uncontrolled Gout, with Orrin Troum, MD
Troum discussed positive efficacy and safety findings from the phase 4 AGILE study.
Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD
Schett discussed findings from 2 early studies of CD19 CAR T-cell therapy.
TCE Therapy Demonstrates Quick Responses for Systemic Lupus Erthematosus in Early Data
A-319 has been well-tolerated so far and dose-escalation is ongoing in the phase 1 trial.
John Stone, MD, MPH: Inebilizumab Efficacious for IgG4-Related Disease in MITIGATE Study
Stone discussed findings from the first randomized, double-blind, placebo-controlled trial for IgG4-related disease.
Glucocorticosteroid Use for Rheumatoid Arthritis Increases CVD, Infection Mortality Risk Even After Cessation
People who used GC for over 2 years and 3 years had elevated risks of CVD and infection-related mortality, respectively, that never returned to pre-GC use levels.
IL-18 Levels Associated With Long COVID Risk in People With Rheumatic Diseases
IL-18 levels were consistently lower across participants with different SARDs, remission status, and COVID-19 disease characteristics.
Study Finds Benefits and Risks in Cannabis Use for Rheumatoid Arthritis
While an effective and promising strategy for chronic pain relief, more research on long-term cannabis usage is needed.
Jinny Tavee, MD, Explores Neurosarcoidosis: The Great Mimicker
Jinny Tavee, MD, explains the potential neurological complications of sarcoidosis, an autoimmune disease that affects multiple systems.
Tracy Frech, MD, MSCI: Digital Ischemia for the Rheumatologist
Tracy Frech, MD, MSCI, explains what rheumatologists need to know about preventing and management digital ischemia.
Smartphone-Based App Demonstrates Clinical Benefits in Fibromyalgia Management
At 12 weeks, significantly more patients with fibromyalgia receiving the smartphone-based intervention reported clinical improvements compared with the control group.
Fibromyalgia Symptoms Unimpacted by COVID-19 Pandemic
Findings may be related to a variety of influences including a slower life pace during the pandemic and resilience to prolonged stressors.
Patient Survey Leads to Better Understanding of Digital Health Preferences in Fibromyalgia
Common themes included preferring a standard list of symptoms, active training programs, and the desire for community.
Wristband, Coaching Program Improves QoL in Patients with Fibromyalgia
A clinically significant percentage of patients with fibromyalgia in the immediate intervention group had greater improvements in quality of life compared with patients in the delayed cohort.
Atul Deodhar, MD: Long-Term Data on Bimekizumab for Ankylosing Spondylitis
During this interview segment, Dr. Deodhar described his presentation at the ACR 2023 convergence on longitudinal data regarding bimekizumab for patients with this condition.
Patients with RA, Long COVID Significantly More Likely to Have Concomitant Fibromyalgia
Fibromyalgia was 3 times more common among patients with rheumatoid arthritis and Long COVID.
John Botson, MD: Pegloticase Plus Immunomodulator Enhances Gout Treatment
John Botson, MD, discusses his study examining real-world pegloticase plus immunomodulation co-therapy using data from an insurance claims database.
Philip J. Mease, MD: New Data on Guselkumab for Psoriatic Arthritis Patients
This interview segment with Dr. Mease featured a discussion about data presented at ACR 2023 on guselkumab and patients with psoriatic arthritis.
AR882 Lowers Serum Urate in Patients with Gout
At month 6, more patients in the AR882 75 mg cohort demonstrated complete resolution of ≥1 tophus compared with patients in the allopurinol cohort.
Brian LaMoreaux, MD: Outcomes Following Discontinuation of Pegloticase Treatment
After a 12-week gap, 5% of patients returned to pegloticase and responded well.
Hospitalized Patients with Gout Show Increased Rates of Concomitant VTE
Approximately 10% of patients with gout had a concomitant diagnosis of venous thromboembolism among nearly 800,000 hospitalizations in the US.
Specific Healthy Plant-Based Diets Resulted in Fewer Cases of Incident Gout
This new data from ACR 2023 suggests that the guidelines on a healthy diet predominantly based on plants have been confirmed with regard to incident gout.
Bimekizumab Improves Spinal Pain, Fatigue, Morning Stiffness in axSpA
At 16 weeks, patients treated with bimekizumab reported greater improvements in both mean spine pain and morning stiffness when compared with placebo. These improvements continued through week 52.
Rituximab Plus Avacopan Increases Remission Rates in ANCA-Associated Vasculitis
Sustained remission was observed in more patients receiving rituximab and concomitant avacopan compared with those treated with concomitant prednisone.
Sustained Serum Urate Reduction for Gout Patients Observed with AR882
In this data shown at ACR 2023, the URAT1 inhibitor known as AR882 showed promising phase 2b data for patients with gout.
Brian LaMoreaux, MD: Use and Efficacy Post-Pegloticase Treatment
The most successful outcomes were observed in patients with at least 6 months of pegloticase therapy who promptly began oral therapy within 60 days.
Telitacicept Efficacious, Safe in Treating Rheumatoid Arthritis Patients with Inadequate MTX Response
In these phase 3 findings presented at ACR 2023, the safety and efficacy of this drug was proven in ACR20, ACR50, and DAS28-ESR responses.
TLC599 Injection Shown to be Effective for Daily Pain in Patients with Osteoarthritis of the Knee
In this late-breaking research shown at ACR 2023, TLC599 injection led to benefits in patients with a single injection and further benefits with a second.
Gary Macfarlane, MD, PhD: The Impact of Fibromyalgia on Treatment Response in PsA
The study revealed that patients meeting fibromyalgia criteria or displaying fibromyalgia-like symptoms were less likely to meet standardized response criteria with biologic therapy.
Afimetoran Shown to be Safe, Well-Tolerated for Patients with Cutaneous Lupus Erythematosus
This new late-breaking data presented at ACR 2023 was the first clinical evidence indicating efficacy of afimetoran for those with CLE.
Diana Abdueva, PhD: Novel Blood-Based Assay Differentiates Seropositive and Seronegative Rheumatoid Arthritis, Healthy Subjects
Diana Abdueva, PhD, states selecting the right therapy for rheumatoid arthritis is a complex challenge due to both the economic burden of therapies and the trial-and-error process patients often undergo.
